Merck & Co., Inc.’s decision to pivot away from COVID-19 vaccine development and toward treatments looks like less of a sure thing as the company is now discontinuing development of MRK-7110, one of two therapies acquired in late 2020, and will focus development of the other candidate, molnupiravir, in outpatients due to lack of benefit in the hospitalized population.
More broadly across the industry, it appears that the wide variety of potential vaccines and therapies that emerged in 2020 has begun to narrow down – as vaccination spreads
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?